Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
-- Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL…
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
-- Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for…
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / - Cellipont Bioservices, a leading cell therapy Contract…
Copyright © 2024 Wugen. All Rights Reserved.
a COGNEO design